tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Asad Haider, 12 are a HOLD (36.36%), 1 are a SELL (3.03%), 20 are a BUY (60.61%).
Analyst Asad Haider, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 93.21% that have a potential upside of 16.51% achieved within 86 days.
Asad Haider’s has documented 65 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 12-Jun-2026.
Analyst best performing recommendations are on NAMS (NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES).
The best stock recommendation documented was for NAMS (NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES) at 12/2/2025. The price target of $37 was fulfilled within 1 day with a profit of $1.33 (3.47%) receiving and performance score of 34.7.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 22-Apr-2025
$53
$-6.12 (-10.35%)
$59
Sell Since 02-May-2022
$41
$-18.12 (-30.65%)
$37
Buy Since 07-Feb-2025
$59
$-0.12 (-0.20%)
$60
8 days ago
(05-Oct-2026)
22/29 (75.86%)
$0.19 (0.32%)
867
Buy Since 22-Apr-2025
$82
$22.88 (38.70%)
$75
27 days ago
(16-Sep-2026)
4/6 (66.67%)
$18.4 (28.93%)
323
Hold Since 17-Mar-2026
$65
$5.88 (9.95%)
$60
1 months 3 days ago
(10-Sep-2026)
4/5 (80%)
$1.25 (1.96%)
206
Which stock is Asad Haider most bullish on?
What Year was the first public recommendation made by Asad Haider?
